Ashwagandha (Withania somnifera) has earned its place as one of the most studied botanicals in the modern nutraceutical industry. With over 100 human clinical trials spanning stress, sleep, cognition, endurance, and hormonal health, it stands as a category-defining adaptogen – and KSM-66® Ashwagandha, among the most clinically studied ashwagandha root extracts, has been a key contributor in building that evidence base.
Yet as consumer demand accelerates and global markets expand, the category faces growing scrutiny. Questions around adulteration, inconsistent quality, and regulatory compliance are sharpening – and the gap between commodity ashwagandha and rigorously standardized, science-backed extracts has never been more consequential.
This spotlight brings together leading experts across clinical science, market intelligence, regulatory strategy, and industry practice to deliver a comprehensive, evidence-driven examination of where ashwagandha stands today. From the latest clinical findings to global market trends and how to approach safety assessments, as well as the persistent challenge of adulteration, this session is designed to give formulators, brands, and R&D professionals the full picture – and the confidence to distinguish between extract standards and evidence levels.
